Ketamine is not a classic psychedelic. It is officially classified as a dissociative anesthetic, a category it has held since the FDA first approved it in 1970. But the line between “dissociative” and “psychedelic” is blurrier than most people assume, and ketamine can produce experiences that overlap with what people report on psilocybin or LSD. The short answer: it belongs to a different drug class, works through a completely different brain mechanism, and produces a distinct type of altered consciousness, but it shares enough territory with psychedelics that researchers increasingly study it alongside them.
How Ketamine Works in the Brain
The clearest reason ketamine isn’t grouped with classic psychedelics is what it does at the molecular level. Psilocybin, LSD, and DMT all work primarily by activating serotonin receptors, especially a subtype called 5-HT2A. Ketamine doesn’t touch that system in any meaningful way. Instead, it blocks a glutamate receptor called NMDA, which plays a central role in how nerve cells communicate with each other throughout the brain.
That difference matters because it creates an entirely different chain of events. When ketamine blocks NMDA receptors, it paradoxically triggers a surge of glutamate, the brain’s main excitatory chemical messenger. At sub-anesthetic doses, this glutamate burst increases connectivity in the prefrontal cortex and kicks off a process where the brain begins building new synaptic connections. That rewiring becomes measurable within 24 hours and can persist for about a week. Classic psychedelics also promote new neural connections, but they get there through a fundamentally different pathway.
How the Experience Differs
If you’ve read trip reports for both ketamine and psilocybin, you’ve probably noticed they sound different. That’s not just subjective preference. Researchers have proposed a model that explains why: ketamine and classic psychedelics disrupt different brain networks.
Ketamine primarily disrupts what’s called the salience network, which maintains your basic sense of being a body in space. This is why the hallmark ketamine experience is dissociation: feeling detached from your physical self, floating, losing track of where your body ends and the room begins. At higher doses, this becomes the “k-hole,” a state of profound disconnection from sensory reality.
Classic psychedelics, by contrast, tend to disrupt the default mode network, which maintains your autobiographical sense of self, your personal narrative, your ego. That’s why the signature psychedelic experience is ego dissolution: the feeling that “you” have temporarily ceased to exist, often accompanied by a sense of merging with everything around you, vivid visual imagery, and emotionally intense insights about your life.
There is overlap. Some ketamine users report visual distortions, mystical feelings, and moments of ego dissolution, particularly at higher doses. And some psychedelic experiences include dissociative qualities. But the dominant flavor of each experience is distinct enough that most users can easily tell them apart.
From Battlefield Anesthetic to Psychiatric Tool
Ketamine’s journey is unlike any classic psychedelic’s. It was first synthesized in 1962 as a safer alternative to PCP, and the first human anesthetic dose was given in 1964 at the University of Michigan. By the 1970s, it was a go-to battlefield anesthetic because it doesn’t suppress breathing or blood pressure the way most anesthetics do.
The psychiatric chapter opened decades later. In 2006, a landmark study showed that a single low dose of ketamine could produce rapid antidepressant effects in people who hadn’t responded to conventional medications. That finding was remarkable because standard antidepressants take weeks to work, while ketamine’s effects appeared within hours. Subsequent research confirmed it could also rapidly reduce suicidal thoughts, something no other treatment had reliably demonstrated.
In clinical trials with treatment-resistant depression, the response rate to repeated ketamine infusions reached about 71%. Among those who responded, the median time before symptoms returned after the last infusion was 18 days, meaning most people need ongoing treatment rather than a one-time fix.
FDA-Approved Uses Today
The FDA has approved a nasal spray form of esketamine (one of ketamine’s two mirror-image molecules) for two specific conditions: treatment-resistant depression in adults, and depressive symptoms in adults with major depression accompanied by acute suicidal thoughts or behavior. It’s available only through a restricted program. You can’t pick it up at a pharmacy and take it at home.
Each dose must be administered in a certified healthcare setting, under direct observation. After treatment, you’re monitored for at least two hours because of the risks of sedation, dissociation, and changes in blood pressure. During the first month, sessions happen twice per week. After that, the frequency tapers to once a week or every two weeks, depending on how well the response holds.
This supervised model is very different from how classic psychedelics are being studied in clinical trials, where the emphasis tends to be on one to three high-dose sessions with extensive psychological preparation and follow-up therapy. Ketamine treatment looks more like a recurring medical appointment.
Why People Call It a Psychedelic Anyway
The word “psychedelic” literally means “mind-manifesting,” and by that loose definition, ketamine qualifies. It alters perception, changes how you experience time and space, and can produce profound shifts in perspective. In popular culture and in many ketamine therapy clinics, the psychedelic label is used freely.
Researchers have started using the umbrella term “psychedelic-assisted therapy” to describe treatments involving ketamine alongside psilocybin and MDMA, partly because the therapeutic frameworks overlap. All three involve altered states of consciousness in a clinical setting, all three appear to open windows of enhanced neural plasticity, and all three are being explored for conditions like depression and PTSD.
But pharmacologically, calling ketamine a psychedelic is imprecise. It’s a dissociative that can produce psychedelic-like effects. That distinction isn’t just academic. It has real implications for what the experience feels like, what risks to expect, and how the drug interacts with other medications. Someone who has used psilocybin should not assume a ketamine experience will feel similar, and vice versa.
Risks Worth Knowing About
Ketamine’s risk profile also sets it apart from classic psychedelics. Psilocybin and LSD carry virtually no risk of physical dependence and are not associated with organ damage. Ketamine is a Schedule III controlled substance with recognized potential for misuse, and repeated use carries a specific physical risk that classic psychedelics don’t: bladder damage.
Ketamine-induced cystitis affects a significant number of regular users. Urinary symptoms, including pain, urgency, and frequency, show up in over 25% of people who use ketamine recreationally. About 20% of frequent users report cystitis-like symptoms compared to roughly 7% of infrequent users. The severity tracks directly with dose and frequency. The damage happens because ketamine and its byproducts pass through the urinary tract and directly irritate the bladder lining, triggering inflammation and, over time, scarring.
This risk is most relevant for people using ketamine frequently or at high doses outside medical supervision. The doses and schedules used in clinical settings are lower, but the connection between cumulative exposure and bladder problems is well established enough that it deserves attention from anyone considering long-term use.